Literature DB >> 11194798

Streptococcus pneumoniae in children in Spain: 1990-1999.

A Fenoll1, I Jado, D Vicioso, S Berrón, J E Yuste, J Casal.   

Abstract

UNLABELLED: This study analyses the serogroups/types (SGTs) and resistance to penicillin and erythromycin of 3921 strains isolated from 1990 to 1999 in children aged 0-14 y in Spanish hospitals of all the autonomous communities. Based on the age of the children, strains have been divided into five groups: 0-6 mo, > 6-1 y, > 1-2 y, > 2-5 y and > 5 y. While only eight SGTs were responsible for 80% of the infections in children from 6 mo to 2 y of age, this number increased to 11 and 16 for the groups > 2-5 y and > 5-14 y, respectively. SGTs 6, 14 and 19 were prevalent in blood and otic exudates. SGTs 1, 4, 5, 12 and 18 were more frequent in invasive disease but serotype 3 was clearly associated with otitis. Serotypes I and 5 were quite significant in children of over 2 y of age, and this should be taken into account in future vaccine formulations.
CONCLUSION: Although high, the rate of penicillin resistance in the paediatric population has remained stable in recent years. Conversely, erythromycin resistance is still increasing in our country. Coverage by the 7-valent vaccine was 78 and 81% for blood and otic isolates, respectively. These coverage levels would be increased by 9% and 3% if 9-valent (plus 1 + 5 serotypes) were used and by an additional 2.6% and 7.6% using the 11-valent (plus 3 + 7) formulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11194798     DOI: 10.1111/j.1651-2227.2000.tb00783.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  8 in total

1.  Analysis of the genetic structure of nontypeable pneumococcal strains isolated from conjunctiva.

Authors:  Sonsoles Berrón; Asunción Fenoll; Montserrat Ortega; Noemí Arellano; Julio Casal
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar.

Authors:  J Picazo; J Ruiz-Contreras; J Casado-Flores; E Giangaspro; F Del Castillo; T Hernández-Sampelayo; E Otheo; F Balboa; E Ríos; C Méndez
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

3.  Clinical data and factors associated with poor outcome in pneumococcal meningitis.

Authors:  Juan Casado-Flores; Javier Aristegui; Carlos Rodrigo de Liria; Jose María Martinón; Cristina Fernández
Journal:  Eur J Pediatr       Date:  2005-12-07       Impact factor: 3.183

4.  Burden of paediatric invasive pneumococcal disease in Europe, 2005.

Authors:  E D G McIntosh; B Fritzell; M A Fletcher
Journal:  Epidemiol Infect       Date:  2006-09-07       Impact factor: 2.451

5.  Effects of specific antibodies against Streptococcus pneumoniae on pharmacodynamic parameters of beta-lactams in a mouse sepsis model.

Authors:  J Casal; L Aguilar; I Jado; J Yuste; M J Giménez; J Prieto; A Fenoll
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

6.  Upper respiratory tract microbial communities, acute otitis media pathogens, and antibiotic use in healthy and sick children.

Authors:  Melinda M Pettigrew; Alison S Laufer; Janneane F Gent; Yong Kong; Kristopher P Fennie; Joshua P Metlay
Journal:  Appl Environ Microbiol       Date:  2012-06-29       Impact factor: 4.792

7.  Pneumococcal bacteremia in children: an 8-year review in two hospitals in Barcelona.

Authors:  A Pérez; P Sala; M Giménez; M Sierra; A Esteve; A Alonso; M Quesada; F Raspall; V Ausina; C Rodrigo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-18       Impact factor: 3.267

8.  Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005.

Authors:  C A Ihekweazu; D A B Dance; R Pebody; R C George; M D Smith; P Waight; H Christensen; K A V Cartwright; J M Stuart
Journal:  Epidemiol Infect       Date:  2007-10-26       Impact factor: 2.451

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.